Intellia Therapeutics, Inc.
0JBU.L
London Stock Exchange17.37
USD
-0.45
- -
Intellia Therapeutics, Inc.
0JBU.L
(London Stock Exchange)
Recent
price
17.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Intellia Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of proprietary CRISPR-based genome editing therapies. The company’s core products and services include the research, development, and manufacturing of in vivo and ex vivo CRISPR/Cas9 gene editing platforms aimed at treating genetic diseases. Intellia’s portfolio encompasses therapeutic candidates targeting rare genetic disorders, including transthyretin amyloidosis (ATTR) and hereditary angioedema, as well as novel programs in areas such as oncology and liver diseases. The company operates primarily in the United States with global research collaborations and partnerships. Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia Therapeutics has recently made significant strategic advancements, including expanding its in vivo therapeutic pipeline and entering new research collaborations with leading pharmaceutical companies. Over the last two years, the company has enhanced its manufacturing capabilities to support late-stage clinical development and potential commercial production. It has also advanced several clinical trials for its lead candidates, securing additional funding rounds to fuel its clinical and research efforts. Intellia remains focused on scaling its operations and strengthening its position in the gene-editing therapeutics market through both organic growth and strategic partnerships. As a key player in the biotechnology industry, Intellia targets patients with severe genetic diseases and complex health conditions that lack effective treatment options. The company is known for its cutting-edge CAR-T cell programming, genome editing therapies, and precision medicine approaches, aiming to transform treatments for rare and serious diseases. Its collaborations extend internationally, reinforcing its footprint across North America, Europe, and potentially other regions through research and licensing agreements. Intellia’s business model integrates proprietary technology development with strategic alliances to accelerate therapeutic innovation and commercialization. This description reflects Intellia Therapeutics’ current product offerings, strategic initiatives, geographic focus, and industry positioning, providing a comprehensive overview consistent with the style of leading financial data providers like Bloomberg, Reuters, and S&P Capital IQ.